MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Inclusion Criteria:

• Have Histological or cytologically proven diagnosis of locally advanced,unresectable, and/or metastatic cancer and measurable disease per ResponseEvaluation Criteria in Solid Tumors (RECIST) version 1.1.

• Have evidence of KRAS G12D mutation in tumor tissue or circulating tumor DNA

• Have an ECOG performance status of ≤ 1

• Must have received ≥ 1 prior line of systemic chemotherapy for advanced ormetastatic disease

• Participants with asymptomatic or treated CNS disease may be eligible.

Exclusion Criteria:

• Have known active CNS metastases and/or carcinomatous meningitis.

• Have any unresolved toxicities from prior therapy greater than National CancerInstitute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade 1.

• Have significant cardiovascular disease as unstable angina or acute coronarysyndrome, history of myocardial infarction, known reduced left ventricular ejectionfraction.

• Have active uncontrolled systemic bacterial, viral, fungal, or parasitic infection.

• Have known active hepatitis B virus (HBV) and hepatitis C virus (HCV).

• Have other active malignancy unless in remission with life expectancy greater than (>) 2 years.